Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC
Institut National de la Santé Et de la Recherche Médicale, France
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Intensity Therapeutics, Inc.
UNICANCER
University of Cincinnati
Helsinki University Central Hospital
Mount Sinai Hospital, Canada